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Cardiac Rehabilitation (CR) is an exercise-based program, aimed at improving ones’ 
cardiovascular health. A substantial majority of patients referred to CR do not enroll, complete, or 
achieve clinical targets in the program due to patient-level factors. The objective of this thesis was 
to investigate relationships between anxiety sensitivity (AnxS) and patient outcomes in CR. Self-
reported questionnaires were completed across two time points, with patient information being 
abstracted from medical records. Stakeholders associated with reducing the burden of AnxS in CR 
were also identified using snow-ball sampling. Findings suggest that resting diastolic blood 
pressure is associated with the interrelationships between AnxS, anxiety, and depression. A larger 
sample size is needed to establish concrete relationships between AnxS and patient outcomes in 
CR. This evidence may support the need to target AnxS for treatment. Stakeholders with high 
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Summary for Lay Audience 
 
 
Cardiac Rehabilitation (CR) is an effective exercise-based program with the goal of improving the 
cardiovascular health of its patients. Across Ontario, most patients who are referred to CR do not 
fully participate, complete, or achieved guideline recommended targets of the program. Research 
has shown that depression and anxiety play a role with these observations. Anxiety sensitivity 
(AnxS) is a personality trait of interest that we believe may impact ones’ ability to obtain the full 
benefits of CR. Individuals with high AnxS feel unsafe or threatened when they experience anxiety 
related symptoms (i.e., increased heart rate). We explored whether individuals with high AnxS 
would engage in less physical activity, less exercise, and not achieve guideline recommended 
targets. We administered 5 self-reported questionnaires at two different times, separated by 6 
weeks. We also collected clinical information from each patient’s medical record.  We observed 
that individuals with high AnxS, high symptoms of anxiety, and high symptoms of depression 
were more likely to report an at-risk diastolic blood pressure. Establishing relationships between 
AnxS and patient outcomes in CR may be important as research suggests that AnxS may be easier 
to treat compared to other psychological factors. This study must be done with more participants 
to make more accurate conclusions of our findings.  We also identified stakeholders of high 
influence and power who could potentially help reduce the burden of AnxS in CR. If after further 
exploration AnxS shows evidence of impacting patient outcomes in CR, these stakeholders could 
help treat AnxS in CR. This can be done by conducting research-based initiatives leading to the 
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Cardiovascular diseases (CVD) are a class of disorders associated with the heart and the 
vasculature, including coronary artery disease (CAD), ischemic stroke, heart failure, arrhythmia, 
and heart valve disease.1 While mortality rates from CVD have trended downward in the last 30 
years 2, the prevalence of people living with CVD has increased, thus  subsequently increasing the 
associated burden on society.3 Cardiac rehabilitation (CR) was first established in the 1970s and 
is supported with strong evidence of reducing mortality and morbidity related to CVD in a cost-
effective manner.4,5 
 
1.1. Cardiovascular Rehabilitation and Secondary Prevention  
 
Contemporary CR programming encompasses cardiovascular rehabilitation and secondary 
prevention, including optimization of pharmacotherapy; for the purposes of this thesis, we will be 
using the acronym “CR” to denote “cardiovascular rehabilitation and secondary prevention”. CR 
programs are delivered by certified clinicians. The Canadian Guidelines for Cardiac Rehabilitation 
and Cardiovascular Disease Prevention describe CR programs encompassing the following: 1. 
Systematic patient referral processes; 2. Patient assessments; 3. Health behaviour interventions 
and risk factor modifications; 4. Adaptations for program models to improve accessibility, 
especially for under-served populations; 5. Development of self-management techniques based 
around individualized assessment, problem-solving, goal setting and follow up; 6. Exercise 
training;  7. Leisure-time activities; 8. Outcomes assessment and performance measurement; and 
9. Continuous quality improvement programs.6,7 In Ontario, CR is considered the standard of care 
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for patients who suffer from or whom have experienced a cardiac-related event.8 For these patients, 
CR plays a critical role in the reduction and control of CVD risk factors.6 The scientific literature 
almost universally supports the effectiveness of CR programs based on well-established evidence 
of reduced morbidity and mortality, healthcare utilization, and increased quality of life.9 Based on 
current clinical guidelines, referral to CR is considered standard of care and part of necessary 
comprehensive care for individuals after the diagnoses of cardiovascular disease (CVD) or a 
cardiovascular event.10,11 
A substantial number of studies have reported on the efficacy of exercise-based CR 
programs to improve quality of life, to reduce the risk of reinfarction, and to reduce the risk of 
cardiac and all-cause mortality (the latter by 20-50%).4 Not surprisingly, CR also results in 
improved exercise capacity,12 which will be discussed in more detail later in this chapter. 
Additionally, cardiovascular disease risk factors such as cholesterol, blood pressure, insulin 
sensitivity, and excess body weight are also improved by CR.4 In addition to individual-level 
benefits, the cost-effectiveness of the program provides promising population-level benefit, 
including but not limited to a reduction in all hospital admissions.13 
Unfortunately, despite the overwhelming evidence to support the cost-effective benefit of 
CR, referral, enrollment, participation, and completion of CR in Canada remain discouragingly 
low due to both system and patient-level barriers. In Canada approximately one-third of eligible 
patients participate in CR.7 Within Ontario, only 22% of eligible patients enroll into CR.7  
 
1.2. System-level Barriers to Optimizing Patient Outcomes in Cardiac 
Rehabilitation 
 
Although patient-level barriers to CR are the focus of this thesis, understanding system-level 
barriers to participation and completion of CR provides general insight on population-level 
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burdens related to CR. Studies have reported insufficient program capacity for eligible patients 
regionally and nationally across Canada. A 2011 analysis of CR capacity in Ontario concluded 
that program availability was only 34%, meaning that 35,000 patients annually were unable to 
access care because of system-level limits on service availability.14 As of 2018, 182 programs were 
active nationally, 72 programs in Ontario, 17 in Quebec, 93 found across the remaining provinces, 
and no CR programs currently exist within the three territories.15 The discrepancy in program 
availability across Canada is reported to be potentially due to differences in provincial 
reimbursement policies.16 For example, CR services provided in Ontario are to the discretion of 
hospital budgets17 in comparison to Quebec where patients are expected to cover CR expenses 
through their individualized insurance coverages.16 Tran et al. has also reported inadequate 
geographic distribution of available programs. A substantial majority of these programs were 
situated in either an urban or suburban regions, thus disproportionally reflecting the need of CR 
across urban and rural populations.15 Additionally, a substantial majority of programs did not have 
another CR program within a 20-kilometer radius.15 This large distance may result in an 
inconvenience for those who do not live near a CR program to participate and complete CR.15 
Referral and enrollment to CR for eligible patients have also been reported to be substantially low, 
being 34%18 and 20%19, respectively.  
 
1.3. Patient-level Barriers to Optimizing Patient Outcomes in Cardiac 
Rehabilitation  
 
In addition to these system-level barriers, there are important patient factors that contribute to sub-
optimal patient outcomes in CR. Patient outcomes are defined as CR enrollment, participation, 
completion, and achievement of clinical targets. Sociodemographic and socioenvironmental 
characteristics are examples of individual level-factors that are associated with these outcomes.7,20 
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For example, due to inadequate government funding, a proportion of CR patients are expected to 
pay the remaining of what is not covered by the Ontario Health Insurance Plan (OHIP), with low 
income patients being largely affected.14 As a consequence, patients residing in low-income status 
neighborhoods are significantly less likely to complete CR compared to those with high-income.21 
There is also evidence that women are less likely to be referred22, enrolled23, and complete CR 
compared to men.24,25  
 In addition to these patient-level factors, there has been an increased awareness of the 
influence of patient mental health factors on patient outcomes in CR. Current research has explored 
the role of depression with regards to sex, age, cardiovascular diagnosis, and CR referral/entry, 
and patient outcomes in a CR program.26,27 Anxiety has also been a mental health factor of interest 
with its relationship between CR clinical outcomes. These relationships have been the focus of 
research to date and will be discussed in more detail within this chapter. More recently, anxiety 
sensitivity (AnxS), defined as a learned cognitive trait that predisposes people to fearful 
interpretations of inner processes and events28, has been investigated for its relationships to both 
depression and anxiety and for its potential role in influencing patient outcomes in CR.   
 
1.4. Depression and Anxiety as Barriers to Participation in Cardiac 
Rehabilitation 
 
Much of the literature supports both depression and anxiety as barriers to optimal patient 
outcomes in CR. Understanding relationships between depression, anxiety, and CR will 





1.4.1. Depression in Patients Participating in Cardiac Rehabilitation 
 
Depression, a range of mood disorders, is both a medical and mental health illness that negatively 
impacts the way affected individuals think, feel, and act on a day-to-day basis.29 “Depression” is 
an umbrella term used to characterize conditions ranging from self-reported depressive symptoms 
and depressive episodes, to clinical diagnoses such as Major Depressive Disorder (MDD) or 
Persistent Depressive Disorder (PDD), among many others, that can and do affect people 
differently at different times.  
 There is an enormous literature on the association between CVD and depression. 
Studies report that about 40% of patients who have suffered a major cardiac-related event have 
also been diagnosed with MDD.30 Multiple studies have reported that depression can both worsen 
the prognosis for multiple CVDs and can also increase the risk of myocardial infarction (MI), and 
stroke.31–34 A recent 2021 review reported that individuals surviving an acute MI have significantly 
lower levels of depression compared to individuals not surviving. Hopelessness, a dimension of 
depression, has been reported to predict all-cause mortality in patients with coronary heart failure 
(CHF). Consistent with these findings, studies have reported depression to be a reliable predictor 
for CVD.35,36 On the reverse side, there is also evidence that CVD may also cause depression.37 
Given the strong association between depression and CVD, it is expected that depression impacts 
patient outcomes in CR. Depressed CR patients are significantly less likely to complete CR.26 In 
addition, gender differences are seen as women report higher levels of depressive symptoms 
compared to men at baseline of CR.38 As a response to this issue, evidence-based guidelines for 
CR have been restructured, recommending that patients be routinely screened for depression due 




1.4.2. Anxiety in Patients Participating in Cardiac Rehabilitation 
 
Anxiety disorders are a group of mental health disorders characterized by frequent, intense, 
excessive fear and worry, and are responses that are substantially different in intensity and 
frequency to “normal” stress responses to common, everyday events.40 Like depression, anxiety is 
an umbrella term used to characterize a spectrum of conditions ranging from self-reported 
symptoms of anxiety to clinical diagnoses such as Generalized Anxiety Disorder (GAD) and Social 
Anxiety Disorder (SAD), among many others. Compared to depression there has been less 
investigation of associations between anxiety and CVD. Nonetheless, anxiety has also been 
reported to be significantly associated with CVD risk factors such as hypertension, specific types 
of CVD such as CAD, heart failure, and an overall increased risk of CVD mortality.41–44 For 
example, 20-30% of patients who have experienced acute coronary syndrome have reported 
elevated levels of anxiety.45,46 Individuals exhibiting higher baseline symptoms of anxiety have 
demonstrated a lower likelihood of completing CR, particularly at the early stages of the 
program.39 Similar to depression, women report higher levels of anxiety compared to men at 
baseline of CR.38 Evidence-based guidelines for CR have also been modified to routinely screen 
for anxiety also due to its high prevalence among those with CVD.39 
 
1.5. Anxiety Sensitivity  
 
This section will aim to define AnxS, discuss distinctions from and relationship to depression and 
anxiety, and explore what is currently known about the relationship between AnxS and CVD, 





1.5.1. Defining Anxiety Sensitivity   
 
AnxS is defined as a learned cognitive trait that predisposes people to fearful interpretations of 
inner processes and events28 and is conceptually distinct from anxiety.47 Whereas anxiety is 
defined as the anticipation of future threat48, AnxS is defined as interpretating physiological 
responses elicited by anxiety as threatening.28 For example, an individual with high AnxS who 
experiences an elevated heart rate after an exercise session, is much more likely than someone with 
low AnxS to respond to the elevated heart rate with excessive fear that they are experiencing a 
heart attack. In the context of the current investigation, AnxS is important to understand because 
of demonstrated and potential associations with other mental health factors, cardiovascular health 
outcomes, and exercise, which have been extensively investigated in CR. AnxS has also been 
evidenced to be targeted for treatment with interventions like cognitive restructuring, 
psychoeducation, interoceptive exposure, and other cognitive behavioural therapy (CBT) styled 
approaches.49 However, the role and potential influence of AnxS has been understudied in CR.  
 
1.5.2. Measuring Anxiety Sensitivity 
  
The measurement of AnxS has evolved over the past two decades, as the construct itself has 
become more precise and the understanding of its component factors has improved. The Anxiety 
Sensitivity Index (ASI original) was developed in 1986. The original ASI consisted of 16 items, 
each item being scored from 1 to 4, with total scores ranging from 0 to 64. Later investigation 
provided evidence that AnxS could be divided into 3 factors: fear of (1) physical symptoms; (2) 
publicly observable anxiety symptoms; and (3) cognitive dyscontrol.50,51 
 In 1998, the Anxiety Sensitivity Index-Revised (ASI-R), consisting of an extensive 
36 items, was developed to prove that AnxS could be divided into multiple factors. Taylor and 
Cox (1998) added a fourth dimension within the AnxS construct: (1) fear of respiratory symptoms; 
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(2) fear of publicly observable anxiety reactions; (3) fear of cardiovascular symptoms; and (4) fear 
of cognitive dysfunction.51 The validity of the ASI-R was later demonstrated in several studies, 
one of which was by Deacon et al. (2003), where they used two non-clinical samples to investigate 
their hypothesis of AnxS having a structure comprised of four dimensions. Although this study 
provided evidence that the ASI-R was more valid and reliable compared to the original ASI, 
several items on the ASI-R reported both the fear of a sensation and the belief that sensations result 
in danger, making the definition of AnxS unclear.52  
 Taylor and Cox (1998) also developed the Anxiety Sensitivity Profile (ASP) which 
added two extra dimensions to the ASI-R: fear of (5) gastrointestinal symptoms; and (6) fear of 
dissociative and neurological symptoms.51,52 This was an attempt to assess additional domains that 
the ASI-R could examine but was not used as much compared to the other AnxS indexes due to 
its length of 60 items. Taylor et al. (2007) then developed the Anxiety Sensitivity Index-3 (ASI-
3), which is a more stable and multidimensional tool used to assess AnxS in both clinical and non-
clinical samples and has also demonstrated greater validity and reliability in comparison to the 
previously designed measures.52,53 With a total of 18 items, each item of the ASI-3 is also scored 
from 1-4, with the total score ranging from 0 to 72.54  
    
1.5.3. Relationships between Anxiety Sensitivity, Depression, and Anxiety 
  
The literature has established AnxS as a distinct construct that can be independently targeted for 
treatment.28 AnxS is also known to be related to anxiety and mood disorders. AnxS is predictive 
of developing a wide range of anxiety related disorders55,56, as individuals with high AnxS are 
more likely to develop an anxiety related disorder compared to those with low AnxS.52,56–58 Studies 
examining the association between AnxS and depression have generally reported an association, 
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though more modest than the association between AnxS and anxiety disorders. Olatunji and 
Wolitzky-Taylor (2009) meta-analysis investigated differences in AnxS between individuals with 
anxiety disorders, depressive disorders, and healthy individuals. Results suggested that 
participants in the anxiety group reported higher AnxS scores compared to those in the mood 
disorder group. Naragon-Gainey (2010) conducted a similar meta-analysis to investigate the 
relationship between AnxS, depressive disorders, and anxiety disorders. Results supported strong 
relationships between AnxS with each of depression, generalized anxiety disorder (GAD), and 
posttraumatic stress disorder (PTSD). Additionally, AnxS was more closely associated to distress 
disorders, such as depression, GAD and PTSD, compared to fear disorders, such as panic, 
agoraphobia, social anxiety disorder, and specific phobias.56 While depression, anxiety, and AnxS 
are similar, they are distinct from each other, each are measured separately, and each are addressed 
differently in a clinical setting. Therefore, there is a need to better understand the role of AnxS and 
its relationship to depression, anxiety, and cardiovascular disease symptomology, along with CR 
adherence and completion in patients enrolled in CR programs. 
 
1.6. Anxiety Sensitivity and its Potential Impact in Cardiac Rehabilitation 
 
1.6.1. Anxiety Sensitivity and Cardiovascular Disease Risk Factors Targeted 
During Cardiac Rehabilitation 
 
A variety of studies have explored the association between AnxS and the traditional CVD risk 
factors, indicators of pre-clinical CVD, and CVD symptoms. For example, Farris and Abrantes 
(2017) demonstrated that smokers with CVD report significantly higher AnxS compared to 
smokers without any cardiovascular health implication.59 The importance of this is key as smoking 
cessation is an important clinical outcome in CR.  
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 Hypertension has been historically noted as a risk factor for CVD, with literature starting 
to report its association with AnxS. Studies suggest that individuals with mild to moderate 
hypertension reported significantly higher AnxS compared to those with normal BP.60,61 Those 
with mild to moderate hypertension did not report significantly more anxiety compared to 
individuals with normal BP60, providing further evidence of a conceptual difference between AnxS 
and anxiety. One study suggests that non-compliance to hypertensive medication may be 
attributable to misinterpretation of normal medication side effects.62 Alcántara et al. (2014) 
reported that nearly double the patients with high AnxS were non-adherent to their BP medication 
compared to those with low AnxS. They concluded that patients with high AnxS were more likely 
to misinterpret their bodily sensations as threatening when they took their BP medication, which 
made them more likely to avoid taking it as prescribed. 
In addition to hypertension, AnxS has been evidenced to be associated with other risk 
factors for CVD. Seldenrijk et al. (2013) suggests that individuals with significantly higher AnxS 
demonstrated a significantly increased likelihood of the presence of carotid plaque and increased 
arterial stiffness, even in healthy patients. Interestingly, depression and anxiety partially mediated 
the association between AnxS and increased stiffness.63 Investigation of anxiety and/or depression 
potentially mediating associations between AnxS and patient outcomes assessed in CR is currently 
understudied and merits further investigation.   
In addition to CVD risk factors, studies have reported associations between AnxS and 
higher levels of self-reported symptoms in patients with CVD. Ong et al. (2006) reported that 
individuals with high AnxS reported significantly greater atrial fibrillation (AF) symptom severity. 
Additionally, Chiaie et al. (1996) reported that AnxS was significantly higher in patients with 
mitral valve prolapse compared to healthy individuals.64  
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 There is emerging evidence that AnxS is associated with CVD risk factors. More research 
is needed to explore whether AnxS can serve as an independent risk factor for incident CVD and 
whether mitigating AnxS in patients with CVD might improve patient outcomes in CR. 
 
1.6.2. Anxiety Sensitivity and Exercise, a Critical Component of Cardiac 
Rehabilitation 
 
Exercise is a key and central component of CR, therefore, understanding what is known about 
AnxS and exercise is important. This section will discuss the associations between AnxS and 
exercise and discuss the impact exercise has on AnxS.  
 
1.6.2.1. Associations Between Anxiety Sensitivity and Exercise  
 
The literature suggests AnxS to be significantly associated with both physical activity and exercise. 
Studies report that individuals with high AnxS engage in significantly less physical activity than 
individuals with low AnxS.65 More specific to aerobic exercise, Hearon and Harrison (2020) 
hypothesized that AnxS would be associated with greater sedentary time. Contrary to their 
hypothesis, AnxS was not a significant predictor for sedentary time, but higher AnxS was 
associated with less aerobic exercise.66 Moshier et al. (2013) also reported that individuals with 
low AnxS engage in significantly more vigorous exercise compared to individuals with high 
AnxS.67 Interestingly, the association was not significant when gender/sex was added to the model; 
the effect of sex on this association will be discussed later in this section. Studies also suggest that 
AnxS is significantly predictive of exercise behaviour, indicating that individuals with high AnxS 
at baseline are significantly less likely to improve their exercise behaviour after one week.68 AnxS 
was also able to predict change in cardiorespiratory fitness measured as peak metabolic equivalents 
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(MET; 1 MET = 3.5 ml O2 / kg body wt / min) achieved on an exercise stress test.68 A review by 
Horenstein, Potter, and Heimburg also addressed this association they investigated AnxS as a 
possible risk factor for chronic medical conditions. They speculate that avoidance of exercise by 
individuals with high AnxS may be due to fear of physiological sensations (e.g., increased heart 
rate) accompanying physiological arousal caused by exercise.69 
 With clear evidence of AnxS being associated with exercise, a few studies evaluated the 
impact of gender in this relationship. McWilliams and Asmundson reported significant 
associations between exercise and AnxS among men but not women, suggesting that only men 
with high AnxS reported less physical activity.70 DeWolfe et al. (2020) conducted a study to 
specifically investigate the gender differences in physical activity, and to determine whether this 
relationship was mediated by AnxS. Their findings suggest that women engaged in significantly 
less physical activity compared to men and AnxS partly mediated the relationship between gender 
and physical activity.71 
 As stated previously, research suggests that body weight may play a moderating role in the 
AnxS and exercise interaction. Hearon et al. (2014) reported that AnxS, body mass index (BMI), 
and their interaction, were predictors for duration engaged in physical activity. Obese individuals 
with high AnxS engaged in less physical activity compared to obese individuals with low AnxS.72 
Smits et al. (2010) reported findings consistent with Hearon et al. (2014), where an interaction 
was found between AnxS, exercise and BMI. Additionally, they reported that fear of exercise was 





1.6.2.2. The Impact of Exercise on Anxiety Sensitivity  
 
Despite the sub-optimal exercise outcomes in individuals with high AnxS, individuals able to 
participate in exercise have demonstrated significant reductions in AnxS. Many studies assessing 
the impact of exercise on AnxS were done using sample sizes of young adults, hence, the 
implications of these studies in relation to CR are uncertain. As previous studies mentioned have 
reported associations between AnxS and tolerance of exercise, studies have reported that 
individuals engaging in a single session of aerobic exercise we able to reduce their AnxS 
significantly more than those who do did not engage in exercise at all.74–76 Broman-Fulks et al. 
(2004) investigated the effects of high vs. low intensity aerobic exercise-induced physiological 
arousal on AnxS. Significant reductions in AnxS were observed in the high intensity exercise 
group, with reduction maintained after a 1-week follow-up.77 In comparison, the low intensity 
exercise group did not demonstrate a significant reduction in AnxS up until 1-week follow-up. 
Consistent with Broman-Fulks hypotheses, a reduction in AnxS after engaging in just low intensity 
exercise is promising, supporting the impact of exercise on clinically relevant psychological 
factors.   
 There is also evidence that gender may moderate the impact that exercise has on AnxS, as 
men have shown a significantly larger reduction in AnxS during exercise treatment compared to 
women.78 Interestingly, Medina et al. also observed no significant difference between genders. 
They speculate the physiological response to exercise could be responsible for the mid-treatment 
difference found between sexes. Sabourin et al. (2011) investigated barriers to exercise in women 
with high AnxS. Results suggested that compared to individuals with low AnxS, individuals with 
high AnxS perceived more barriers and benefits to exercise.79 Notably, they also demonstrated that 
individuals who perceived more barriers than benefits to exercise reported significantly lower 
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fitness scores compared to individuals who perceived more benefits to barriers.79 This may elicit 
clinical complications for treating anxiety-related disorders among high AnxS individuals who 
perceive more barriers than benefits to exercise.  
 Zvolensky et al. observed that individuals who engaged in exercise did not only 
significantly reduce their AnxS, but also demonstrated abstinence from smoking compared to 
individuals who did not exercise.80 As previously mentioned, the importance of this finding is key 
as smoking cessation is a patient outcome assessed in CR. Additional studies comment on 
relationships between AnxS, smoking, and exercise, but that analysis is beyond the scope of this 
thesis.  
 Studies have also evaluated the effectiveness of CBT combined with exercise. Sabourin et 
al. (2016) reported reductions of AnxS in individuals who engaged in a combined CBT and 
exercise treatment compared to individuals who were educated on the importance of exercise, 
nutrition, and sleep81, although this study was done exclusively with women. Consistent with 
findings reported by Sabourin, Smits et al. (2008) reported that AnxS was reduced significantly 
post-treatment and at follow-up evaluations of a combined CBT and exercise treatment. 
Additionally, AnxS mediated the relationship between both depression and anxiety with exercise 
with mediation being stronger among individuals with high AnxS.82 As previously mentioned, 
depression and anxiety are routinely assessed in CR, so this finding may provide clinical 
implications. 
 Reported reductions in AnxS using exercise, CBT, or both is promising as it supports the 




1.6.3. Anxiety Sensitivity and Cardiac Rehabilitation  
 
To date, only two studies have investigated AnxS in CR. Farris et al. (2018) explored the 
association between AnxS and fear related to negative consequences of exercise in CR 
participants. On average, patients reported a moderate level of AnxS, yet of those patients, nearly 
one-third of them reported high AnxS.83 Further analysis deemed AnxS to be associated with fear 
of exercise, with patients being more likely to drop out of either centre-based or home-based 
programs. In a more recent study by Kraemer et al., analysis was done to examine the effects of 
each dimension of AnxS (physical, cognitive, and social) on exercise tolerance. Opposed to the 
previous study, this investigation focused on patients enrolled in a cardiopulmonary rehabilitation 
program.  Consistent with previous studies, it was reported that increased levels the physical 
dimension of AnxS were associated with low exercise tolerance.84 Kraemer et al. speculate that 
individuals with cardiopulmonary conditions reporting high AnxS may experience distress when 
exertion-related symptoms (i.e. elevated heart rate) are stimulated in patients, subsequently 
resulting in exercise avoidance. Given the limited literature on the direct role of AnxS in CR, this 
area of research merits further investigation. 
 
1.7. Summarizing and Synthesizing Existing Literature: What is known 
and Knowledge Gaps about the Role of Anxiety Sensitivity in Cardiac 
Rehabilitation 
 
To date there has been very little investigation of AnxS in relation to CR patient outcomes. Current 
evidence demonstrates that AnxS is significantly related to anxiety, yet more moderately related 
to depression. As depression and anxiety are important influencers of deleterious CR outcomes, 
understanding the concurrent relationships among AnxS, depression, and anxiety within CR may 
have important clinical implications. Key existing literature that evaluates AnxS and its 
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associations with a variety of patient outcomes has also been highlighted. Though limited, a few 
studies have indicated that increased AnxS is associated with hypertension, heart disease, and other 
CVD risk factors. Further investigation is needed to understand what the relationship is between 
AnxS and changes of these variables in individuals participating in CR. Importantly, studies with 
exercise have reported that individuals with high AnxS engage in less physical activity compared 
to individuals with low to moderate AnxS. More promising results, however, have indicated that 
even participating in just one 30-minute session of exercise may significantly reduce AnxS. It is 
important to understand the relationship between AnxS and exercise as it and physical activity are 
fundamental components of CR. Psychological treatment has also been reported to decrease AnxS 
both independently and in combination with exercise, which indicates a potential target for 
treatment. By investigating the relationships between AnxS and these factors within the scope of 
CR, possible mitigation interventions can be designed to increase CR participation and achieve 
appropriate risk factor targets in CR. As stated earlier in this chapter, much of the current literature 
focuses on a much younger population. This thesis will study a CR population by collecting and 






It has been firmly established that CR is both efficacious and cost-effective, yet participation in 
and completion of CR remain alarmingly low across Ontario. Anxiety, and especially depression, 
are important barriers to patient completion of CR. In addition to depression and anxiety, 
understanding the importance of AnxS and how it may mediate or moderate the impact of 
depression and anxiety on CR outcomes is advancing.  
 The novelty of this thesis is in prospectively investigating whether AnxS influences 
patient outcomes in CR, as targeting AnxS for treatment may provide clinical therapeutic benefit. 
Evidence demonstrates that while anxiety and depression are  associated with worse CR outcomes, 
AnxS is associated with each of these, and compared to them, may be a modifiable psychological 
factor to target for treatment.28 Therefore, the overall research problem of this thesis is to 
investigate whether AnxS is associated with patient outcomes in cardiac rehabilitation.  
 
2.1. General Hypothesis  
 
We hypothesized that individuals with high anxiety sensitivity enrolled in cardiac rehabilitation 








2.2. Using a One Health Approach to Address the Research Question 
 
2.2.1. What is One Health and What is a One Health Approach 
 
The term One Health was first used following the occurrence of the severe acute respiratory 
syndrome (SARS) virus and avian influenza H5N1, when the link between animal and human 
health started to become recognized as threatening.85 According to the Centers for Disease Control 
and Prevention (CDC), One Health is defined as a “collaborative, multisectoral, and 
transdisciplinary approach — working at the local, regional, national, and global levels — with 
the goal of achieving optimal health outcomes recognizing the interconnection between people, 
animals, plants, and their shared environment.”86 The CDC adds that “One Health is an approach 
that recognizes that the health of people is closely connected to the health of animals and our 
shared environment. One Health is not new, but it has become more important in recent years. This 
is because many factors have changed interactions between people, animals, plants, and our 
environment.” Stakeholder involvement is a fundamental way to facilitate collaboration both 
within and across multiple sectors at the local, regional, national, and global levels. Khan et al. 
(2018) evaluated the functioning of collaboration of stakeholders within and between One Health 
networks in Africa, Asia, and Europe. Their results suggest the need and importance of increasing 
collaborations across sectors and paying more attention to the environmental health aspect of the 
approach.87 The Public Health Agency of Canada (PHAC) has also highlighted disease 
surveillance, response, and prevention as key features that make up One Health.88  
Historically, zoonotic disease, vector-borne disease (i.e. rift valley fever)89, and additional 
communicable disease complications have benefitted from using a One Health approach to resolve 
health issues. However, there is growing recognition of the need to extend this approach to chronic 
diseases.86 
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2.2.2. The Application of the One Health Approach to Address the Research 
Question 
 
Addressing the research question using the One Health approach was done by: 1. Applying the 
PHAC version of the health problem in CR, addressing human, animal, and environmental aspects 
of One Health; and 2. Engagement of multisectoral stakeholders along the continuum of 
prevention, detection, and treatment to develop and implement realistic solutions that optimize the 
health and well-being of participants enrolled in CR.  
Human health is one of the core pillars within the One Health framework that may have 
clinical implications in CR. As previously mentioned in Chapter 1, the prevalence of people living 
with CVD has increased, subsequently increasing the associated burden on society.3 To evaluate 
the influence of this pillar, relationships between AnxS and CVD risk factors in CR were 
investigated.  
To address the environmental pillar of One Health, the influence of social environmental 
factors on AnxS was investigated. Amid the COVID-19 pandemic, individuals across the globe 
have been faced with prolonged social isolation due to extensive social distancing measures.90,91 
Arguably, older individuals have been impacted the most by set social distancing guidelines, with 
many self-reporting loneliness.90,91 In a cross-sectional study exploring adverse outcomes 
associated with loneliness, high self-reported loneliness was associated with greater depression 
and anxiety.92,93 Loneliness was also associated with increased CVD93, implying an interaction 
between the social environmental and human health pillar. Social environmental factors, such as 
marital status, and its impact on AnxS were investigated. Though exploring the influence of 
COVID-19 in CR was beyond the scope of this thesis, it played a huge part of the context within 
this thesis.   
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Although animal health was not directly investigated in this thesis, translational animal 
models have also played a significant role when investigating CVD and its associated adverse 
outcomes. Research with small animals such as mice and rabbits have been advantageous and are 
continuously used to advance our knowledge on the progression and mechanisms associated with 
CVD.94 CVD translational research has supported the importance of and clear need to mitigate 
adverse cardiac outcomes experienced by individuals through CR. This is yet another example of 
the interconnection between the human and animal health pillars in the One Health approach.  
Collaboration among transdisciplinary stakeholders play a critical role in preventing, 
detecting, and mitigating adverse health outcomes.85,86 There is currently a gap in knowledge 
dissemination and implementation strategies when clinically relevant publications are produced.95 
Bridging this gap through stakeholders is a key component of the One Health approach. In this 
thesis, identified stakeholders who can contribute to reducing the burden associated with AnxS, 
depression, and anxiety may have clinical implications in CR. The use of stakeholders has proven 
to be effective when mitigating adverse outcomes associated with infectious diseases.85  
To fully investigate the clinical implications of AnxS in CR and to formulate possible 
mitigation strategies, a One Health approach was employed in this thesis.  
 
 
2.3. Aims and Hypotheses (Revised) 
 
Specific Aim 1: To investigate the associations between anxiety sensitivity and sociodemographic, 
socio-environmental, and clinical characteristics at initial assessment of CR enrollment. 
Hypothesis 1a: Females will have higher levels of anxiety sensitivity compared to males. 
Hypothesis 1b: Individuals with partners will have lower levels of anxiety sensitivity 
compared to individuals without partners. 
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Hypothesis 1c: Individuals with higher levels of anxiety sensitivity will have less 
favourable clinical characteristics. 
 
Specific Aim 2: To investigate interrelationships between anxiety sensitivity, symptoms of 
anxiety, and symptoms of depression, and how these are associated with CVD risk factor 
characteristics at initial assessment of CR enrollment. 
Hypothesis 2: Individuals with higher levels of anxiety sensitivity combined with higher 
symptoms of anxiety and/or depression will have less favourable CVD risk factor 
characteristics. 
 
Specific Aim 3: To determine if anxiety sensitivity at initial assessment predicts change in 
physical activity, exercise capacity, and diet at 6-week follow-up. 
Hypothesis 3: Individuals with higher levels of anxiety sensitivity will have smaller 
improvements in physical activity, exercise capacity, and diet after 6-week follow-up. 
 
Specific Aim 4: To identify key stakeholders within different disciplines who have the power, 
influence, and potential to assist in investigating, preventing, and mitigating the burden associated 




3.0. Materials and Methods   
 
In this chapter, Section 3.1 through Section 3.7 will explain the methods used to address aims 1-
3, while section 3.8 through to the end of the chapter will intend to address aim 4. 
 
3.1. Study Design  
  
This study used an observational, prospective, longitudinal cohort design for patients referred to 
and participating in the Cardiac Rehabilitation and Secondary Prevention Program at St. Joseph’s 
Health Care London. The sample consisted of consecutively consenting patients. Approval was 
obtained by the Health Sciences Research Ethics Board (HSREB) at Western University and the 
Lawson Health Research Institute in London, Ontario. Copies of both approval letters can be seen 
in Appendix A of this thesis. In response to the Provincial state-of-emergency and Guidance from 
Provincial (CorHealth Ontario)96 and National (Canadian Cardiovascular Society) 97 bodies, the 
St. Joseph’s CR program shifted to virtual delivery of CR programing in the spring of 2020 which 
continued throughout the summer of 2020 (see Appendix B for detailed flow diagram).  
 
3.2. CR Program for Patients in this Study  
 
Due to the COVID-19 pandemic, CR programming was completed on a virtual basis. This was the 
mode of delivery for all patients going through CR in this study. Virtual CR programming 
comprised of multi-disciplinary interventions to optimize patients’ physical activity, exercise, 
nutrition, anxiety, depression, and pharmacotherapy risk profiles.12 As restrictions eased in the fall 
of 2020, virtual programming continued, with some cardiopulmonary exercise test (CPET) 
assessments resuming as necessary for appropriate clinical care. CPET assessments included 
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evaluation of resting and peak measures of heart rate and blood pressure (systolic and diastolic), 
as well as metabolic assessments such as VO2 peak.  
 
3.3. Study Outcomes  
 
There is one primary outcome for the revised study, as follows: 
1. Primary: 
a.  Changes, and/or improvement in clinical characteristics for patients enrolled in the 
cardiac rehabilitation and secondary prevention program. 
b. Achievement of clinical/therapeutic outcomes for patients enrolled in the cardiac 
rehabilitation and secondary prevention program. Note, because most patients in 
this study have only completed initial assessment, achievement of these targets 
cannot be evaluated at this time. 
 
Definition of Primary Outcomes 
Per evidence-based clinical care guidelines and standards defined for CR in Canada98,  there are 7 
therapeutic outcomes defined for patients. A description of these therapeutic goals and a brief 
overview of how we will be quantifying and measuring these goals in this study is included below1:  
 
(1) Physical activity: Cumulative minutes – By the time of discharge, patients would be 
expected to achieve a total of 150 minutes of physical activity each week.98 Minutes of 
physical activity will be measured via the Godin Leisure-Time Questionnaire (GODIN), a 
validated self-reported questionnaire that consists of 4 questions.99 The first 3 questions are 
scored based on frequency of vigorous, moderate, or mild engagement of physical activity 
 
1 A complete copy of each self-reported tool is included in Appendix C of this document. 
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for at least 15 minutes in the past week, multiplied by 9, 6, and 3, respectively and then 
totally.100 Scores were than categorized into active (24 points or more), moderately active 
(14 to 23 points), or sedentary (less than 14 points).100 Godin and Sheppard reported strong 
reliability of this assessment tool by assessing leisure-time physical activity across different 
populations, different countries, and different seasons.100 The tool has also been 
successfully validated to be correlated with percentile VO2 max and percentile body mass, 
which are two determinants of physical fitness, with p-values of <0.001 and <0.01, 
respectively.  
(2) Exercise: Exercise capacity – the therapeutic goal is to achieve a 0.5 MET increase from 
baseline to discharge.98 A MET is defined as a unit expressing rate of oxygen consumption 
while performing a specific activity. This was approximated using the Duke Activity Status 
Index (DASI), which is a reliable and validated self-reported questionnaire consisting of 
12 questions.101 The total DASI score ranged from 0 to 58.2 points.102 Raw DASI scores 
were then converted to METs to estimate peak rate of oxygen intake. Hlatky reported a 
significant spearman correlation (0.80) between DASI scores and peak oxygen intake, 
supporting its validity in estimating METs.101 Scores were than categorized into poor (1-4 
METs), moderate (4-7 METs), good (7-10 METs), or excellent (over 10 METs) level of 
METs achieved.103  
(3) Diet – the therapeutic goal for all patients who enter CR is to be offered clinical support 
and education on making dietary changes consistent with the Mediterranean Diet.98 In this 
study, dietary status was assessed using the Mediterranean Diet Questionnaire (MDQ), 
which is a reliable, validated self-reported questionnaire consisting of 14 questions.104–106 
Each question was given a score of either 0 or 1, with total score ranging from 0 to 14. 
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Scores were then categorized into low (score of 5 or less), moderate (score between 6 to 
9), or high (score of 10 or more) levels of adherence to the Mediterranean diet.104  
(4) Blood pressure – the specific therapeutic target for blood pressure is tailored to each patient 
based on a complex algorithm as established by the Hypertension Canada Guidelines.98,107 
The general target for each patient is 140/90 mmHg. The resting diastolic and systolic 
blood pressures were categorized as within target (<90mmHg/<140mmHg) or at risk 
(>90mmHg/>140mmHg). All measurements were abstracted from the patient’s health 
record.107 
(5) Blood lipids – the therapeutic goal was a low density lipoprotein (LDL-c) reduction of 50% 
or a level of <2 mmol/L.98 Non-high-density lipoproteins (non-HDL-c) were assessed in 
this study and categorized as within target (<2.6mmol/L) or at risk (>2.6mmol/L). All 
measurements were abstracted from the patient’s health record.108  
(6) Glucometabolic control – this was determined by the level of hemoglobin A1c (HbA1c) as 
recommended by the Canadian Diabetes Association guidelines98,109, HbA1c was 
categorized as meeting target (<7.0%) or at risk (>7.0%).110 All HbA1c measurements were 
abstracted from the patient’s health record.  
 
3.4. Study Predictor Variables (Independent Variables)  
 
Key objectives for this study were to better understand AnxS, how it may impact outcomes from 
CR, and how it may interrelate with anxiety and depression to impact outcomes from CR. For this 
study, these key constructs (independent variables) were measured as follows:  
 
(1) Anxiety Sensitivity: This was measured using ASI-3, which is a reliable and validated 
questionnaire, compared to earlier versions of the tool, comprised of 18 questions (see 
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Section 1.5.2.).52,53 An internal consistency test reported the reliability of each of the 3 
subscales within the questionnaire with Cronbach consistency scores above 0.70.  Factorial 
validity was confirmed across six replication samples in both clinical and non-clinical 
populations.53 Each question was scored from 1 to 4, with total scores ranging from 0-72. 
Scores were categorized into high (greater than 22 points), moderate-to-high (17-22 
points), or low (less than 17 points) levels of AnxS.111  
 
(2) Symptoms of Anxiety: This was measured using the Patient Health Questionnaire-4 (PHQ-
4), which is a reliable, validated questionnaire which has been routinely used as part of 
standard of care in CR.112 Further, the PHQ-4 has been reported to be sensitive for detecting 
change in health status across a 3-month timespan.113 The PHQ-4 is comprised of 4 
questions, 2 of those questions specifically address anxiety. Each of the questions were 
scored from 0-3, resulting in a total possible score of 6. A clinical cut off score of 3 was 
used to identify an individual exhibiting high levels of anxiety.114 
 
(3) Symptoms of Depression: This was measured using the Patient Health Questionnaire-4 
(PHQ-4), with the remaining 2 questions specifically addressing depression.112 Scoring and 
clinical cut off scores for symptoms of depression are identical to symptoms of anxiety on 
the PHQ-4 as mentioned above.  
 
3.4.1. Covariates  
 
Additional variables (covariates), including information regarding age, patient demographics, and 
clinical characteristics, were necessary to understand key relationships between the predictor 
variables (AnxS, anxiety, and depression) and study outcomes (defined above) to address the 
research question using the One Health approach. All necessary sociodemographic (biological 
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sex), socio-environmental (marital status), and clinical characteristics (adherence to Mediterranean 
diet, resting blood pressures, blood lipid, and blood glucose) were abstracted from the patient’s 
medical record, maintained by the CR Program at St. Joseph’s Health Care London.  
 
3.5. Participant Enrollment and Consent   
 
A complete overview of the patient referral, study screening, consenting process, and the data 
collection process is included in the study flow diagram (See Figure 1 of Appendix B). 
Patients are referred to the CR Program at St. Joseph’s Health Care London, by a physician 
(family practitioner, cardiologist, or another specialist). Upon receipt of this referral, the clinical 
team at the CR Program at St. Joseph’s Health Care London mails each referred patient a 
comprehensive information packet including information about their CR intake appointment, as 
well as a general research pamphlet (UWO REB approved) informing them that they may be 
contacted for interest in taking part in research activities within the CR Program at St. Joseph’s 
Health Care London; this pamphlet allows for the research staff to directly contact patients if the 
patients do not opt-out from being contacted (refer to Figure 1 in Appendix B for the opt-out 
process). Patients indicating that they did not want to learn more about the study or that they were 
not interested in participating, were not contacted further. Patients not indicating any of the 
previously mentioned were then screened by the research team for eligibility in the study. Patients 
were eligible to join if it was their first time enrolling in a CR program. Patients were considered 
ineligible if they were unable to complete the verbal informed consent unaided and/or enrolled in 
the Atrial Fibrillation Navigator study, the latter being because they were or could have been 
enrolled in related research.  
Patients not indicating that they were not interested in participating were then contacted by 
the research team to: (1) determine method of sending the letter of information to the patient, and 
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(2) schedule a follow-up appointment at a time of their convenience, to review the letter of 
information and complete verbal informed consent. Patients were then sent a copy of the 
documented consent via mail or email per patient preference. (See Figure 1 in Appendix B). Once 
consent was received, the patient was then successfully enrolled into the study.  
 
3.6. Study Procedures 
 
For this study, procedures included completion of self-reported questionnaires by participants and 
abstraction of data from the electronic medical record for CR Program at St. Joseph’s Health Care 
London. As described in detail below, participants were asked to complete these questionnaires at 
initial assessment and at 6-week follow-up points during their 6-month participation in the CR 
program. This data was collected between February to July of 2021. Information relating to study 
outcomes and covariates were abstracted from the electronic medical record. Information on 
medication was not collected or included in this study due to the lack of variation between 
participants, making such data not as informative. A summary of the data collection procedures is 








Data Collection Period 
Primary Outcomes 
 
Physical Activity GODIN 
Initial assessment and 6-week 
follow-up 
Exercise Capacity DASI 
Diet MDQ 
Blood Pressure  




Intake of CR Blood Glucose Control 
(HbA1c) 



















Intake of CR 
 
Abbreviations: GODIN, Godin leisure-time Questionnaire; DASI, Duke Activity Status Index; MDQ, Mediterranean 





Following consent, arrangements were made with each consenting participant regarding the 
collection of the self-reported questionnaires. As part of the previously mentioned informed 
consent process, participants were given options in which they preferred to complete the 
questionnaires. The available options were as follows: 
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a. Phone call – The student researcher will call the participant and go through all questions 
on each questionnaire via REDCap. REDCap is a hospital approved web-based data 
management system that lets participants directly answer questions. REDCap stores 
information following the hospital security guidelines and policies.  
b. Videocall – The student researcher will videocall the participant via WebEx, a hospital 
approved application, and complete each questionnaire. Data from each questionnaire will 
be documented and stored in REDCap.  
c. Mail – The student researcher will send a prepaid postage envelope with all questionnaires 
enclosed. The participant will be responsible for sending back the envelope with all 
questionnaires completed. Once the questionnaires are returned, the student researcher will 
replicate the responses into REDCap.  
d. Online via REDCap – The student researcher will email the participant a link to REDCap 
for them to complete the questionnaires independently online.  
 
Participants were also given an optional reminder one week prior to their next set of questionnaires 
– options for reminders included either a phone call, email, or mail out. Participants enrolled in 
the study who had not completed questionnaires on their scheduled date were sent up to two 
reminder requests over the course of the subsequent three weeks. If they did not complete those 
questionnaires, they were not contacted until the next scheduled time point for data collection.  
 
3.7. Data Management  
 
As previously mentioned, all data completed by participants in this study were confidentially 
added into REDCap by either a member of the research team or directly by the participant 
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themselves. REDCap was also setup to include a scoring algorithm for each of the self-reported 
questionnaires – data abstracted from REDCap included answers to each question and each 
participant’s respective score for each questionnaire.  
 
3.8. Data Analysis 
 
All statistical analyses were performed using SPSS software.115 Descriptive analytic approaches 
such as mean, standard deviation, and proportions were used to characterize sociodemographic, 
socio-environmental, and clinical characteristics of participants. A test of normality was conducted 
for each of the study outcomes using the Shapiro-Wilk Test. Dependent on the outcome of 
normality, study outcomes were reported with either means and standard deviations, or median 
and 25th/75th percentiles.  Due to non-normal results of reported GODIN, DASI, and blood pressure 
data using the Shapiro-Wilk test, we exclusively relied on the Chi-Square, a univariate statistical 
test, to investigate the relationship between AnxS and the study outcome variables for the 
following reasons: 
a. Appropriate test to use for non-normality of the tested variables  
b. Addresses the challenges of outliers in the small sample size in the study  
c. Results are easily interpretable using this test 
 
Although adherence to Mediterranean diet scores, blood lipid, and blood glucose data were 
reported as normal, to be consistent with how we evaluated non-normal data, the Chi-Square Test 
was used. The use of other statistical tests (i.e., t-tests and regression) will be revisited when a 





3.9. Identifying Key Stakeholders  
 
An element of an approach used by the RECARE project116 was used in this thesis to systematically 
identify a diverse range of stakeholders to investigate, prevent, and mitigate the burden associated 
with the mental health factors in CR. The first step was to establish identification criteria between 
the student researcher and members of research committee. This allowed for a common objective 
to be set about the purpose of each stakeholder and their potential engagement in their project.116 
Identification criteria established for this was to incorporate multidisciplinary stakeholders, as 
characterized by the One Health definition85,86,  across the following four sectors: 1. academia; 2. 
advocacy groups; 3. government and 4. non for-profit organizations. Stakeholders from all sectors 
were affected by or affected the burden associated with AnxS in CR. This was determined by 
assessing the official websites of these stakeholders for this information. In addition, all 
stakeholders had relation to one or more of the 3 pillars of One Health (human, animal, and 
environmental health). The second step of the approach was to provide key identification 
characteristics of the stakeholders such as their location, level of function (local, regional, 
national), and level of interest (field of activity, form of role, and their sector).116 Next, an 
extension of existing stakeholder networks were created using “snowball sampling”.116 For the 
purposes of this thesis, members of the research committee served as the first identified 
stakeholders. The snowball sample framework was applied twice by using a Google search engine 
to collect relevant information relating to the research team and identifying affiliated stakeholders 
through the official websites of each stakeholder. The primary focus of the search was to identify 
positions and organizations of the stakeholders rather than naming them. The stakeholders were 
then categorized by sector, location, regional jurisdiction, field of activity/role, and rank of 
influence. Rank of influence was estimated using a score between 1 (high), 2 (moderate), or 3 
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(low) determined by the current position held by the stakeholder, their ability to lead research in 
CR, and their ability to implement system-level changes to established guidelines and/or access to 
health care services. A rank of 1 represented a high level of power/influence, a rank of 2 
represented a moderate level of power/influence, and a rank of 3 represented a low level of 
power/influence. The final phase of this approach was to determine possible mitigation strategies 
using the stakeholders with the highest power/influence. Accordingly, identified stakeholders with 
a rank of influence equal to 1 were then grouped with a reporting of their potential impact of 














4.0. Results  
 
A total of 186 patients who enrolled in CR were forwarded to the research team to screen for 
eligibility. Of the 186 patients, 7 patients were not eligible to join the study, 68 participants 
consented to participate in the study, 59 of consented participants completed baseline 
questionnaires for this study, and 31 completed 6-week follow-up questionnaires. A more detailed 
breakdown can be seen below in Figure 1. 
 
 





























Sociodemographic, socio-environmental, and clinical characteristics of participants who 
completed baseline questionnaires were reported as presented in Table 2. Most participants were 
male and under the age of 65. Sociodemographic and socio-environmental characteristics 
demonstrated that most participants lived in an urban area (76.2%), were married or in common-
law (64.4%), and were either retired or worked full-time (76.3%). Clinical characteristics 
demonstrated that the top 3 reasons for referral were individuals with coronary angioplasty 
(27.1%), coronary artery bypass grafting (16.9%), and (repaired) valvular heart disease (11.9%). 
It is important to note that some participants may have been referred for more than 1 event. Most 
participants reported a BMI (derived from reported weight and height) in the overweight (33.3%) 
or obese range (31.7%), with a majority not reporting any history of diabetes (71.2%). Most 
participants reported a history of hypertension (54.2%), dyslipidemia (62.7%), and CVD (62.7%). 
Additionally, a vast majority of patients reported no history of a sedentary lifestyle (93.2%).  
 
Table 2: Sociodemographic and Socio-environmental, and Clinical Characteristics of Study 
Participants 
N 59 
Male (%) * 78.0 
Age, median/mean (SD), y  









Sociodemographic/Socioenvironmental Characteristics   





























Clinical Characteristics  
Reason for Referral, % 
CHF 
CABG 




Unstable Angina Pectoris  
































NYHA Score, % 
1 = No symptoms  
2= Mild symptoms 







CCS Score, % 96 
0= Asymptomatic  
1= Presence of angina during strenuous, rapid, or 







Mean BMI, kg/m2 * 
BMI category, % 
<18.5 (underweight) 
18.5 to 24.9 (normal) 
25 to 29.9 (overweight) 










































Smoking Status, % 


















Abbreviations for Table 2 above: AF, atrial fibrillation; BMI, body mass index; CCS, Canadian Cardiovascular 
Society; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CVD, cardiovascular disease; 
ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NYHA, New York Heart Association; SCAD, 
spontaneous coronary artery dissection 
 
 
Study outcomes were tested for normality, with reported means, medians, and levels of variance. 
Using a Shapiro-Wilk test, (error) distributions of physical activity, exercise capacity, resting 
diastolic blood pressure, and resting systolic blood pressure deviated significantly from normality 
(p<0.05). In contrast, scores of adherences to the Mediterranean diet, non-HDL-c, and HbA1c did 
not deviate significantly from normality (p>0.05). A detailed description of findings can be found 
below in Table 3.   
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40.5 mins  
(25.0/59.2) 
Active  
(24 pts+): 67.8 
 
Moderately Active  















7.2 METs  
(5.7/9.0) 
Excellent  
(10+ METs): 0 
 
Good  
(7-10 METs): 52.5 
 
Moderate  
(4-7 METs): 37.3 
 
Poor  
(1-4 METs): 3.4 
 
Missing: 6.8 






7.7 pts  
(2.5) 
High Adherence  
(10+pts): 25.0 
 
Moderate Adherence  
(6-9pts): 50.0 
 
Low Adherence  













At Target  
(<90mmHg): 78.0 
 


























At Target (<140mmHg): 
61.0 
 











3.0mmol/L (1.3) At Target (<2.6mmol/L): 
39.0 
 











6.0% (0.9) At Target  
(<7.0%): 72.9 
 







Abbreviations for Table 3 above; HbA1c, hemoglobin; HDL-c, high density lipoprotein cholesterol  
 
Study predictor variables were tested for normality, with reported means, medians, and levels of 
variance. Using the Shapiro-Wilk test, study predictor variables were tested for normality. Results 
suggest that AnxS, symptoms of depression, and symptoms of anxiety did not meet the criteria to 
be normally distributed (p<0.001). Reports suggest that 35% of participants have moderately high 
to high AnxS while most participants did not have symptoms of depression (76.3%) and anxiety 








Table 4: Descriptive Statistics for Study Predictor Variables 













Anxiety Sensitivity: ASI-3 * 12.0 (7.8, 19.0)  High ‡  
(22+pts): 20.0 
 
Moderately High ‡  
(17-22pts): 15.0 
 






Symptoms of Depression: 
PHQ-4 *  
1.0 (0, 2.0)  High (3-6 pts) †: 22.0 




Symptoms of Anxiety: 
PHQ-4 * 
1.0 (0, 2.0)  High (3-6 pts) †: 16.9 





‡Cut-points for ASI-3 were established by Allan et al. 2014 111 
†Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression 




4.1.    Results: Associations between Anxiety Sensitivity, Sociodemographic, 
Socio-environmental, and Clinical Characteristics  
 
In this section, the results of analyses addressing specific aim 1 are presented.  
Specific Aim 1: investigate the associations between anxiety sensitivity and 
sociodemographic, socio-environmental, and clinical characteristics at initial assessment.  
Hypothesis 1a: Females will have higher levels of anxiety sensitivity compared to 
males.  
Hypothesis 1b: Individuals with partners will have lower levels of anxiety 
sensitivity compared to individuals without partners. 
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Hypothesis 1c: Individuals with higher levels of anxiety sensitivity will have less 
favourable clinical characteristics. 
 
Univariate associations between AnxS, sociodemographic, socio-environmental, and clinical 
characteristics were assessed using a Chi-Square test with results presented in Table 5. Results 
indicated that AnxS was not significantly associated with sex, marital status, physical activity, 
exercise capacity, adherence to the Mediterranean diet, resting diastolic blood pressure, resting 
systolic blood pressure, non-HDL-c, and HbA1c at initial assessment (p>0.05). The association 
between adherence to the Mediterranean diet and AnxS was the only study outcome to approach 
statistical significance (p=0.074). This suggests that there may be a trend of individuals with high 
AnxS reporting low adherence to the Mediterranean diet.  
 
Table 5: Associations between Anxiety Sensitivity, Sociodemographic, Socio-environmental, 
and Clinical Characteristics at Initial Assessment 
Dependent 
Variable 
ASI Category:  
Low (<17 pts)  




(17-22 pts)  
(n, % within ASI 
category) 
ASI Category:  
High (>22 pts)  








Sex * Male: 27, 81.8 
 
Female: 5, 15.2 
Male: 7, 77.8 
 
Female: 2, 22.2 
Male: 10, 83.3 
 







Married: 21, 70.0 
 
Not Married: 9, 30.0 
Married: 7, 77.8 
 
Not Married: 2, 22.2 
Married: 8, 72.7 
 








(24+ pts): 22, 78.6 
 
Moderately Active 




(24+ pts): 7, 100 
 
Moderately Active 




(24+ pts): 7, 58.3 
 
Moderately Active 









ASI Category:  
Low (<17 pts)  




(17-22 pts)  
(n, % within ASI 
category) 
ASI Category:  
High (>22 pts)  











(10+ METs): 0,0 
 
Good  
(7-10 METs): 17, 56.7 
 
Moderate  
(4-7 METs): 13, 43.3 
 
Poor  
(1-4 METs): 0,0 
Excellent  
(10+ METs): 0,0 
 
Good  
(7-10 METs): 6, 75.0 
 
Moderate  
(4-7 METs): 1, 12.5 
 
Poor  
(1-4 METs): 1, 12.5 
Excellent  
(10+ METs): 0,0 
 
Good  
(7-10 METs): 5, 41.7 
 
Moderate  
(4-7 METs): 6, 50.0 
 
Poor  








(10+ pts): 10, 31.3 
 
Moderate  
(6-9 pts): 18, 56.3 
 
Low  
(5 or less pts): 4, 12.5 
High  
(10+ pts): 1, 11.1 
 
Moderate 
(6-9 pts): 6, 66.7 
 
Low 
(5 or less pts): 2, 22.2 
High  
(10+ pts): 3, 30.0 
 
Moderate  
(6-9 pts): 2, 20.0 
 
Low  








Within Target  
(<90mmHg): 26, 96.3 
 
At Risk  
(>90mmHg): 1, 3.7 
Within Target  
(<90mmHg): 6, 100.0 
 
At Risk  
(>90mmHg): 0,0 

















At Risk  
(>140mmHg): 9, 33.3 




At Risk  
(>140mmHg): 0,0 
Within Target  
(<140mmHg): 9, 81.8 
 
 
At Risk  








At Risk  
(>2.6mmol/L): 17, 
60.7 
Within Target  
(<2.6mmol/L): 4, 50.0 
 
At Risk  
(>2.6mmol/L): 4, 50.0 
Within Target  
(<2.6mmol/L): 5, 41.7 
 
At Risk  




HbA1c * Within Target  
(<7.0%): 24, 82.8 
Within Target  
(<7.0%): 7, 87.5 
Within Target  





ASI Category:  
Low (<17 pts)  




(17-22 pts)  
(n, % within ASI 
category) 
ASI Category:  
High (>22 pts)  








At Risk  
(>7.0%): 5, 17.2 
 
At Risk  
(>7.0%): 1, 12.5 
 
At Risk  




Abbreviations for Table 5 above: MET, Metabolic Equivalent; HbA1c, Blood Glucose; Non-HDL-c, non-high 
density lipoprotein cholesterol; NSS, not statistically significant (p>0.05) 
 
4.2.    Results: Interrelationships between Anxiety Sensitivity, Anxiety, 
Depression, and Clinical Characteristics 
 
In this section, the results of analyses addressing specific aim 2 are presented.  
Specific Aim 2: To investigate interrelationships among anxiety sensitivity, symptoms of 
anxiety, and symptoms of depression, and how these are associated with clinical 
characteristics at initial assessment.  
Hypothesis 2: Individuals with higher levels of anxiety sensitivity 
combined with higher symptoms of anxiety and/or depression will have less 
favourable clinical characteristics. 
 
 Univariate associations between anxiety and depression, as measured using the PHQ-4, were 
assessed using a Chi-Square test. The associations reported in Table 6 support that there is a 
statistically significant association between the anxiety and depression subscales within the PHQ-









Table 6: Associations between Symptoms of Depression and Symptoms of Anxiety 










(0-2 pts)  
High 






(0-2 pts)  




91.1 8.9 100.0 
Within Anxiety 
Category (%) 
85.4 40.0 77.6 
High 
(3-6 pts) † 




53.8 46.2 100 
Within Anxiety 
Category (%) 
14.6 60.0 22.4 
Total 




82.8 17.2 100 
Within Anxiety 
Category (%) 
100 100 100 
*Missing Data 
†Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression 
 
Univariate associations between AnxS and symptoms of anxiety were assessed using a Chi-Square 
test. The associations presented in Table 7, support that there is a statistically significant 






Table 7: Associations between Anxiety Sensitivity and Symptoms of Anxiety 
  























(0-2 pts)  




66.7 17.8 15.6 100.0 
Within AnxS 
Category (%) 
93.8 88.9 58.3 84.9 
High 
(3-6 pts) † 




25.0 12.5 62.5 100.0 
Within AnxS 
Category (%) 
6.3 11.1 41.7 15.1 
Total 




60.4 17.0 22.6  
Within AnxS 
Category (%) 
100.0 100.0 100.0 100.0 
*Missing Data 
†Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression 
Abbreviations for Table 7 above: AnxS, anxiety sensitivity  
 
Univariate associations between AnxS and symptoms of depression were assessed using a Chi-
Square test. The associations presented in Table 8, reported that associations between AnxS and 








Table 8: Associations between Anxiety Sensitivity and Symptoms of Depression 























(0-2 pts)  




68.3 12.2 19.5 100.0 
Within AnxS 
Category (%) 
87.5 55.6 66.7 77.4 
High 
(3-6 pts) † 




33.3 33.3 33.3 100.0 
Within AnxS 
Category (%) 
12.5 44.4 33.3 22.6 
Total 




60.4 17.0 22.6 100.0 
Within AnxS 
Category (%) 
100.0 100.0 100.0 100.0 
*Missing Data 
†Scores 3 or greater are recognized in clinical settings as a positive screen for symptoms of anxiety and depression 
Abbreviations for Table 8 above: AnxS, anxiety sensitivity; NSS, not statistically significant  
 
The implications of creating a new variable to investigate the interrelationships among the three 
constructs and their impact of patient outcomes in CR can be found in the discussion section of 
this thesis. A new variable was created with three categories representing the extent to which 
participants had 1,2, or 3 of high AnxS, high symptoms of anxiety, and high symptoms of 
depression. The “null group” were those participants with low AnxS, symptoms of anxiety, or 
symptoms of depression. The “all group” were those who presented with high AnxS and high 
symptoms of anxiety and high symptoms of depression. The “some group” were those who 
presented with a mix of some high and some low levels of AnxS, symptoms of anxiety, or 
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symptoms of depression. Of the 53 participants that had complete data for all 3 scores, there were 
4 participants in the “All Group” (7.5%), 36 were in the “Some Group” (67.9%), and 13 
participants were in the “Null Group” (21.7%).  
 Univariate associations between this new variable, representing the impact of overlapping 
AnxS, symptoms of anxiety, and symptoms of depression were assessed using a Chi-Square test, 
with the results presented in Table 9. There were statistically significant associations (p<0.05) 
between this category and diastolic blood pressure, suggesting that individuals in the “Null” group 
met the guideline recommended target significantly more frequently than individuals in the “All” 
group. It is worth noting that only 1 participant in the “All” group reported not being within target.  
No additional associations were found between this new variable, physical activity, exercise 
capacity, Mediterranean diet adherence, resting systolic blood pressure, non-HDL-c, and HbA1c 
(p>0.05).  
 
Table 9: Associations between High Levels of Anxiety Sensitivity, Anxiety, Depression and 




High AnxS, Anxiety 
and Depression 
(n, % within ASI 
category) 
Some Group: 
Mix of High and/or 
low AnxS, Anxiety, 
and Depression 
(n, % within ASI 
category) 
Null Group: 
Low AnxS, Anxiety, 
and Depression 











(24+ pts): 3, 75.0 
 
Moderately Active 
(14-23 pts): 0,0 
 
Sedentary  
(<14 pts): 1, 25.0 
Active  
(24+ pts): 25, 83.3 
 
Moderately Active 
(14-23 pts): 4, 13.3 
 
Sedentary  
(<14 pts): 1, 3.3 
Active  
(24+ pts): 8, 66.7 
 
Moderately Active 
(14-23 pts): 2, 16.7 
 
Sedentary  






(10+ METs): 0,0 
 
Excellent  
(10+ METs): 0,0 
 
Excellent  








High AnxS, Anxiety 
and Depression 
(n, % within ASI 
category) 
Some Group: 
Mix of High and/or 
low AnxS, Anxiety, 
and Depression 
(n, % within ASI 
category) 
Null Group: 
Low AnxS, Anxiety, 
and Depression 








(7-10 METs): 1, 25.0 
 
Moderate  
(4-7 METs): 3, 75.0 
 
Poor  
(1-4 METs): 0,0 
Good  
(7-10 METs): 19, 57.6 
 
Moderate  
(4-7 METs): 12, 36.4 
 
Poor  
(1-4 METs): 2, 6.1 
Good  
(7-10 METs): 7, 58.3 
 
Moderate  
(4-7 METs): 5, 41.7 
 
Poor  





(10+ pts): 1, 25.0 
 
Moderate  
(6-9 pts): 1, 25.0 
 
Low  
(5 or less pts): 2, 50.0 
High  
(10+ pts): 9, 25.0 
 
Moderate 
(6-9 pts): 21, 58.3 
 
Low 
(5 or less pts): 6, 16.7 
High  
(10+ pts): 4, 36.4 
 
Moderate  
(6-9 pts): 4, 36.4 
 
Low  









Within Target  
(<90mmHg): 2, 66.7 
 
 
At Risk  
(>90mmHg): 1, 33.3 




At Risk  
(>90mmHg): 0,0 













Within Target  
(<140mmHg): 1, 33.3 
 
 
At Risk  
(>140mmHg): 2, 66.7 




At Risk  
(>140mmHg): 6, 22.2 









Non-HDL-c * Within Target  
(<2.6mmol/L): 1, 25.0 
 
 
At Risk  
(>2.6mmol/L): 3, 75.0 




At Risk  
(>2.6mmol/L): 16, 
51.6 









HbA1c * Within Target  
(<7.0%): 3, 75.0 
 
Within Target  
(<7.0%): 26, 83.9 
 
Within Target  








High AnxS, Anxiety 
and Depression 
(n, % within ASI 
category) 
Some Group: 
Mix of High and/or 
low AnxS, Anxiety, 
and Depression 
(n, % within ASI 
category) 
Null Group: 
Low AnxS, Anxiety, 
and Depression 







At Risk  
(>7.0%): 1, 25.0 
At Risk  
(>7.0%): 5, 16.1 
At Risk  
(>7.0%): 1, 8.3 
*Missing Data 




4.3.    Results: Investigating Anxiety Sensitivity as a Predictor of Change in 
Physical Activity, Exercise Capacity, and Adherence to the 
Mediterranean Diet  
 
In this section, the results of analyses addressing specific aim 3 are presented. Of the 59 
participants who completed baseline questionnaires, 31 (52.5%) completed 6-week follow-up 
measures. 
Specific Aim 3: To determine if anxiety sensitivity at initial assessment predicts change in 
exercise capacity, physical activity, and diet at 6-week follow-up. 
Hypothesis 3: Individuals with higher levels of anxiety sensitivity will have 
smaller increases in exercise capacity, physical activity, and diet after 6-week 
follow-up. 
Univariate associations between AnxS, physical activity, exercise capacity, and adherence to the 
Mediterranean diet at 6-week follow-up were assessed using a Chi-Square test, with results 
presented in Table 10. Clinical variables presented in the table were measured once at the 6-
week period. No significant associations were reported (p>0.05).  
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ASI Category:  
Low  




 (Score 17-22)  
(n, %) 













(24 pts+): 13, 76.5 
 
Moderately Active 
(14-23 pts): 2, 11.8 
 
Sedentary  
(<14pts): 2, 11.8 
Active  
(24 pts+): 2, 100.0 
 
Moderately Active 





(24 pts+): 6, 66.7 
 
Moderately Active 
(14-23 pts): 1, 11.1 
 
Sedentary  






(10+ METs): 0,0 
 
Good  
(7-10 METs): 6, 46.2 
 
Moderate  
(4-7 METs): 7, 53.8 
 
Poor  
(1-4 METs): 0,0 
Excellent  
(10+ METs): 0,0 
 
Good  
(7-10 METs): 2, 66.7 
 
Moderate  
(4-7 METs): 1, 33.3 
 
Poor  
(1-4 METs): 0,0 
Excellent  
(10+ METs): 0,0 
 
Good  
(7-10 METs): 7, 77.8 
 
Moderate  
(4-7 METs): 1, 11.1 
 
Poor  







(10+ pts): 5, 26.3 
 
Moderate  
(6-9 pts): 10, 52.6 
 
Low  
(5 or less pts): 4, 21.1 
High  
(10+ pts): 1, 33.3 
 
Moderate 
(6-9 pts): 2, 66.7 
 
Low 
(5 or less pts): 0,0 
High  
(10+ pts): 0,0 
 
Moderate  
(6-9 pts): 5, 71.4 
 
Low  














4.4.     Identified Stakeholders with Potential to Reduce Burden Associated 
with Anxiety Sensitivity in Cardiac Rehabilitation  
 
In this section, the results of analyses addressing specific aim 4 are presented.  
Specific Aim 4: To identify key stakeholders within different disciplines who have the 
power, influence, and potential to assist in investigating, preventing, and mitigating the 
burden associated with anxiety sensitivity in CR. 
After conducting a comprehensive “snowball sample” of relevant stakeholders, 21 were identified 
within the academic (n=10), advocacy (n=8), government (n=1), and non-for-profit (n=2) sectors 
(See Table 11 below). Identified stakeholders with an estimated rank of influence equal to 1 were 
then grouped with a reporting of their potential impact of reducing the burden associated with 
AnxS in CR. 
 
Table 11: Identified Multidisciplinary Stakeholders with Potential to Reduce Risk of Burden 




Field of Activity/Role 
Rank of 
Influence 
Sector: Academia  
Medical Director 









Works clinically and 
academically to reduce 
burden, and improve 
clinical outcomes 
associated with CR  
1 (High) 








An expert on the impact 
of exercise in CR. Works 
clinically and 
academically to reduce 
burden, and improve 
clinical outcomes 












Works academically to 
optimize patient 
outcomes in post-acute 

















Extensive knowledge in 
Cardiovascular health 
and the influence of 
psychology 
2 (Moderate) 
Beryl and Richard 
Ivey Research 











to the use of mental 




Beryl Ivey Chair 
















Encourages One Health 
through academic 












research, and outreach 











Works clinically and 
academically with animal 
health. Potential to 
advance translational 
research on the influence 
of AnxS on 
cardiovascular disease 
3 (Low) 






Encourages One Health 
through academic 
research and student-led 
committees 
3 (Low) 






Provincial  Primary focus on 
healthcare policy and 
planning improvement. 
Facilitated collaboration 
between CCN and OSN 
organizations, leading to 
the founding of 
CorHealth 
1 (High) 




National Enhances knowledge, 






Field of Activity/Role 
Rank of 
Influence 
research within the scope 
of CR 







Focuses on care provided 
by CR program. 
1 (High) 




Provincial Works to fulfill 
CorHealth mandate of 
improving the healthcare 
system by leading the 









Provincial Works on psychotherapy 
treatments on range of 
mental health disorders. 
Potential to investigate 






Global  Launched Mental Health 
Initiative for Universal 
Coverage  
3 (Low) 
One Health Club London, 
Ontario 






Local Student-led committee 
advocating for the 




Minister of Health 
in Ontario  
Toronto, 
Ontario 
Provincial Responsible for 
governing and managing 
the healthcare system on 
Ontario population-level  
1 (High) 










influence of social 
determinants of health on 
mental health outcomes. 
Has 7 years of 
experience working on a 
multi-stakeholder.  
1 (High) 




National  Leading funder for 
cardiovascular related 
research. Potential to 
invest in research 
targeting AnxS for 
treatment in CR 
2 (Moderate) 
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Abbreviations for Table 11 above: AnxS, Anxiety sensitivity; CACPR, Canadian Association of Cardiovascular 
Prevention and Rehabilitation; CCN, Cardiac Care Network; CMHA, Canadian Mental Health Association; CPRP, 
Cardiovascular Prevention and Rehabilitation Program; CR, Cardiac rehabilitation; CRNO, Cardiac 
Rehabilitation Network of Ontario; CRSP, Cardiac Rehabilitation and Secondary Prevention; NGO, Non-
governmental organization; OPN, Ontario Psychological Association; OSN, Ontario Stroke Network; UHN, 
University Health Network; WHO, World Health Organization 
 
 
Table 12: Identified Stakeholders with the Highest Estimated Potential Power and Influence 
Stakeholder Regional Jurisdiction  Potential Impact of Direct 
Influence  
Health Minister of Ontario Provincial Potential to administer 
funding and provide access to 
support psychological 
services aimed to treat AnxS 
in CR.  
Medical Director of CRSP 
Program at St. Joseph’s 
Health Care London 
Local, provincial Ability to conduct a 
collaborative clinical trial 
with Toronto Rehabilitation 
on the efficacy of treating 
AnxS in CR. This stakeholder 
also has established 
relationships with members 
of the CACPR. This may help 
with implementing changes to 
the CACPR guidelines if 
AnxS treatment provides 
clinical benefit. 
Director of CPRP at Toronto 
Rehabilitation, UHN 
Local, provincial Ability to conduct a 
collaborative clinical trial 
with CRSP program at St. 
Joseph’s Health Care London 
on the efficacy of treating 
AnxS in CR. 
Director of Research, CR, 
Peter Munk Center, UHN 
Local, provincial This stakeholder is an active 
member of the CACPR. They 
have the potential to 
communicate the efficacy of 
AnxS treatment to board 
members, with efforts to 
modify guidelines where 
applicable. 
Senior Vice President of 
CorHealth Ontario 




based recommendations of 
treating AnxS to the CACPR. 
President of the CACPR National Potential to lead and 
implement changes to the 
CACPR on the burden 
associated with AnxS, 
grounded by evidence-based 
research conducted by 
clinical trials.  
Interim Chair of CRNO Local, provincial Potential advocate to the 
CACPR on guideline 
modifications relating to 
treatment of AnxS. 
National Chief Executive 
Officer of CMHA 
Local, provincial, national Potential to guide 





















This longitudinal cohort study, despite being curtailed by the COVID-19 pandemic to 59 
participants, provides a novel evaluation of relationships between AnxS and patient outcomes in 
CR.  
 
5.1. Characteristics of the Study Sample  
 
 Due to COVID-19, CR was completed virtually by patients. Subsequently, participation in this 
study was also completed virtually, making this group of participants a unique “COVID-19 
cohort”. As a direct consequence to delays in clinical care due to COVID-19, research activities 
were also delayed, impacting the number of participants enrolled in this study. Therefore, it is 
important that enrollment continues beyond the completion of this thesis to increase the statistical 
power of this study.  Of eligible patients, about 38% consented to participate in the study. Of the 
participants who consented, 87% completed questionnaires at initial assessment, and of the 
participants who completed questionnaires at initial assessment, about 53% completed follow-up 
surveys. This data speaks to study performance of this cohort. Despite a low sample size, clinical 
characteristics (i.e., age and reason for referral) of this cohort were consistent with similar studies 
done in CR.83,84 However, this cohort was more physically active and presented with a good level 
of exercise capacity at initial assessment than anticipated. This may have been due to this cohort 
being a relatively younger sample compared to other CR samples, as approximately 20% of the 
cohort was under the age of 50. Results also suggested that a vast majority of participants (75%), 
moderately adhered to the Mediterranean diet. Results also suggested that about half of the 
participants (50.8%) did not meet the guideline recommended target for blood lipid control (non-
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HDL-c), while most participants (72.9%) attained the guideline recommended target for blood 
glucose control (HbA1c) at baseline. This suggests that this cohort may be healthier than other CR 
cohorts but needs further investigation to support this claim. 
 
5.2. Anxiety Sensitivity and Patient Outcome Characteristics  
 
Previous studies have reported associations between gender and AnxS, suggesting that women 
report significantly higher AnxS compared to men. Inconsistent with those findings and our 
hypothesis, sex and physical activity were not significantly associated with AnxS in this study. 
This may be due to the current study investigating these relationships in CR in which previous 
studies did not. Additionally, the sample size reporting sex was low (n=58), creating implications 
for statistical power. Future studies should re-test this association with a larger sample size to 
ensure these findings are accurate. Previous studies have also reported associations between 
physical activity and AnxS, suggesting that individuals more physical active report significantly 
lower AnxS compared to those who are sedentary. Based on our cohort being more active than 
anticipated, we did expect to detect an association. However, physical activity was not associated 
with AnxS. This may be due to much of the literature reporting associations in a younger and non-
clinical population. It may also be due to a low sample size of those reporting level of physical 
activity (n=47). Future studies should re-test this association with a larger sample size to ensure 
these findings are accurate. Interestingly, results indicate that individuals with high AnxS may 
have low adherence to the Mediterranean diet, however it does warrant further study and additional 
sample size to ensure that this was not a spurious observation. No other associations between AnxS 
and the remaining socio-environmental and clinical characteristics were found, which were not 
expected. This may also be due to lack of statistical power, therefore, these associations merit 
further investigation with a larger sample size to ensure these findings are accurate. If significant 
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associations are found with a larger sample size, this may suggest the need to target AnxS for 
treatment, as individuals with high AnxS will be less likely to report favourable patient outcomes 
in CR.  
 
5.3. Anxiety Sensitivity, Anxiety, and Depression 
 
Previous studies have reported associations between AnxS, anxiety, and depression. Consistent 
with the findings from the literature, results from this study reported 2 key relationships. 
Significant associations between symptoms of depression and symptoms and anxiety were 
observed in this cohort as expected, and consistent with previously reported observations.117 More 
importantly, reported significant associations between AnxS and symptoms of anxiety in this study 
may provide clinical implications in CR. Based on the literature, we expected significant 
associations between AnxS and symptoms of depression, however, this association only 
approached significance likely due to low statistical power. With symptoms of anxiety and 
depression being routinely screened and treated in CR, the need to understand whether routine 
screening and treatment of AnxS in CR is beneficial merits further investigation. With insufficient 
sample size to investigate the interrelationships among AnxS, symptoms of anxiety, symptoms of 
depression, and their impact on patient outcomes in CR, the creation of a new variable was a 
preliminary step used to address this question with the data obtained. Additionally, associations 
between AnxS, the “All”, “Some”, and “Null” groups, suggest that individuals with high AnxS, 
and positive PHQ-4 screens on symptoms of anxiety and depression, reported a resting diastolic 
blood pressure outside of the recommended target range. No other associations between AnxS, 
symptoms of anxiety and depression, and additional CR clinical characteristics were found. Based 
on the findings of association between AnxS, depression, and anxiety, we expected to see more 
associations between AnxS and the study outcomes. However, we did not observe these 
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associations potentially due to lack of statistical power. Future studies should evaluate the same 
associations with a larger sample size to ensure the relationships observed are accurate.    
 
5.4. Anxiety Sensitivity and Clinical Progress in Cardiac Rehabilitation 
 
Currently, the literature suggests that AnxS is a predictive marker for change in exercise 
behaviour.68 We expected that AnxS at initial assessment would be a predictive marker for change 
in physical activity at 6-week follow-up, however no significant associations were found. 
Moshier’s study involving a much younger cohort68 may explain why no relationship was observed 
as the cohort in this thesis was significantly older than that of Moshier’s. Secondly, only 31 
participants completed follow-up questionnaires, indicative of low statistical power. Additionally, 
AnxS at initial assessment did not predict physical activity, exercise capacity, and adherence to 
the Mediterranean diet at 6-week follow-up.   
Strong evidence suggests that CR improves patient outcomes and reduces burden related 
to CVD.4 Despite the efficacy of CR, individuals with high AS have reported fear or exercise 
which may be related to CR dropout.83 If AnxS at baseline is proven to be a predictive marker for 
clinical characteristics at 6-week follow-up, this may provide a better a predictor for CR dropout, 
supporting the need to treat AnxS. The evaluation of this relationship with a larger sample size 
merits further investigation which may provide clinical implications.  
 
5.5. Stakeholder Implications  
 
Stakeholders play an essential role both independently and collaboratively in improving patient 
outcomes associated with AnxS in CR. The RECARE approach has been an effective framework 
for identifying stakeholders in a systematic and collaborative style as indicated with the RECARE 
project.116 The RECARE project was applied to a large transdisciplinary research project, where a 
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broad network of stakeholders was created.116 This approach allowed for stakeholder identification 
to be directly part of the research methodology by establishing criteria for stakeholder 
identification and allowing identified stakeholders to recruit potential stakeholders who could 
positively impact the outcomes of the study. Using this process, stakeholder implications in this 
thesis were more applicable to the research question.  
 Research, advocacy, and policy modifications are common themes seen across many key 
stakeholders that aim to effectively support the healthcare needs of patients enrolled in CR. 
Academia has proven to be essential in conducting research relevant to cardiovascular health. To 
reduce the burden associated with AnxS, clinicians and researchers are on the forefront of 
conducting clinical trials to target AnxS for treatment within CR. Additionally, provincial 
healthcare providers with executive roles provide population-level benefit as they often are 
involved in overseeing the clinical and economic decisions related to improving the healthcare 
system. The provincial government is another example of a potential stakeholder that carries high 
power and influence. Resource allocation to support clinical trials and possible changes to routine 
care in CR is one way they can make a clinical impact.  
 Based on these findings, categorizing identified stakeholders based on level of influence, 
interest, and power is both an efficient and effective way to reduce the burden associated with 
AnxS in CR, as those with higher influence, interest, and power, will likely provide substantial 
impact.  
 
5.6. Strengths and Limitations  
 
The strengths of this study include its novelty along with its prospective study design – information 
obtained from this study will be relevant for individuals that have been recently diagnosed with or 
that currently suffer from a cardiac condition. The prospective aspect of the study will allow us to 
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draw casual inferences about the potential to target AnxS for treatment for those enrolled in a CR 
program. By observing the impact of AnxS on socio-environmental, sociodemographic, and 
clinical characteristics, this study is novel in applying a One Health approach to investigate a 
research problem specific to CR. Identification of multisectoral stakeholders highlighted an 
additional key element of the One Health approach and may allow future studies to test the efficacy 
of stakeholder engagement in improving patient outcomes in CR. Due to the impact of COVID-
19, the findings from this study should be interpreted with a few limitations in mind. Firstly, 
selection bias may have impacted this study in the following ways: a. the pandemic may have been 
related to why the cohort was relatively younger compared to previous CR cohorts – this may have 
played a role in higher than expected fitness of the sample; b. a long delay of intake into CR had 
an unknown effect on patients who agreed to wait to enroll in CR – this may have impacted 
associations reported in Chapter 4; c. virtual care in CR may have added unknown implications of 
enrolled patients as prescribed exercises, for example, were not routinely monitored; and d. lower 
enrollment of those eligible to participate in CR directly impacted the number of eligible patients 
for this study. Psychological measurements during this study may have also been affected by 
conditions caused by COVID-19 – this could include feelings of hopelessness, anxiousness, and 
little to no interest in doing things, which are characteristics evaluated through the PHQ-4. Future 
analysis of this study should aim to compare PHQ-4 scores from this cohort to a previous “non-
COVID” cohort. Additionally, this study did not account for participants who could have been 
undergoing CBT treatment for AnxS. Future analysis should take this into consideration when 
interpreting the results. A stakeholder limitation was the use of the snowball sampling method. All 
stakeholders were identified from one source as opposed to obtaining them from initially identified 
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stakeholders. Future research should aim to include direct involvement of stakeholders when 
creating a multidisciplinary network of stakeholders.  
 
5.7. Contributions and Future Directions  
  
To date, this is one of the first prospective studies to investigate the relationships between AnxS 
and patient outcomes in CR, and the first study to investigate this relationship during the COVID-
19 era, as previous studies have investigated similar relationships cross-sectionally. Benefits to 
this study design allowed for changes in characteristics to be evaluated in the target population. 
However, based on the findings of this study, repeating this study with a larger sample size post-
pandemic may provide more substantial support for the need to routinely assess AnxS in CR if 
significant associations are reported.  
 This study is also one of the first studies to identify transdisciplinary stakeholders with high 
power, influence, and interest in investigating, preventing, and mitigating the burden associated 
with AnxS in this study population. While evidence supports the effectiveness of using the One 
Health approach to implement change within the realm of infectious disease, many aspects of the 
approach can be transferred to non-communicable diseases. Future studies should directly engage 
with identified stakeholders to conduct clinical trials on treating AnxS in CR, translating the results 
of the clinical trial to the appropriate stakeholders, and implementing system-level changes to 










6.0. Conclusion  
 
This study provides some evidence for the importance of evaluating AnxS in CR. Although no 
significant associations were reported between AnxS, sociodemographic, socio-environmental, or 
clinical characteristics, we were able to provide some evidence of association between AnxS and 
adherence to the Mediterranean diet. We were also able to provide evidence consistent with the 
literature of significant associations between symptoms of anxiety and symptoms of depression, 
significant associations between AnxS and anxiety, and some evidence of association between 
AnxS and depression. We were also able to provide evidence of the associations between resting 
diastolic blood pressure and the combined presence of high AnxS, a positive screen for symptoms 
of depression, and a positive screen for symptoms of anxiety as reported by the PHQ-4. This 
association was based on a small sample size and must be re-evaluated using a larger sample. 
Important to the One Health approach, we were able to provide evidence of powerful and 
influential stakeholders that may assist in reducing the burden associated with AnxS in CR.  
 Unfortunately, due to a small sample size, most analyses lacked the statistical power 
to be thoroughly investigated. As a result of these findings, we propose that a larger sample size is 
needed to observe more accurate findings of this study. Additionally, the significant associations 
reported in this study also lacked statistical power and should also be re-analysed with a larger 
sample size and with different parametric tests (i.e., t-test and regression) to ensure reported results 
are accurate. We also propose that snowball sampling of stakeholders be obtained directly from 
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Patient Health Questionnaire – Four (PHQ-4) Questions and Scoring  
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Godin Leisure-Time Questionnaire – Instructions for Scoring 
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Duke Activity Status Index (DASI) – Questions and Scoring  
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 Original Aims and Hypotheses 
 
Specific Aim 1: To investigate the associations between anxiety sensitivity and cardiac 
rehabilitation and secondary prevention clinical outcomes for patients participating in the 
cardiac rehabilitation and secondary prevention program. 
Hypothesis 1a: Individuals with higher levels of anxiety sensitivity at the beginning 
of a cardiac rehabilitation and secondary prevention program will have lower levels 
of participation and will be less likely to complete the program.  
Hypothesis 1b: Individuals with higher levels of anxiety sensitivity at the beginning 
of a cardiac rehabilitation and secondary prevention program will be less likely to 
attain the expected therapeutic targets for the program, including exercise capacity, 
blood pressure control, and blood lipid control.  
Specific Aim 2: To investigate changes in anxiety sensitivity during the course of a cardiac 
rehabilitation and secondary prevention program, and how these changes in anxiety 
sensitivity are associated with clinical outcomes for patients participating in a cardiac 
rehabilitation and secondary prevention program.  
Hypothesis 2a: Anxiety sensitivity will decrease during the course of a cardiac 
rehabilitation and secondary prevention program. 
Hypothesis 2b: Individuals with higher reductions in anxiety sensitivity will have 
higher levels of participation and will be more likely to complete a cardiac 
rehabilitation and secondary prevention program.  
Hypothesis 2c: Individuals with higher reductions in anxiety sensitivity will be 
more likely to attain the expected therapeutic targets for a cardiac rehabilitation and 
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secondary prevention program including, exercise capacity, blood pressure control, 
and blood lipid control. 
Specific Aim 3: To investigate the interrelationships between anxiety sensitivity, 
symptoms of anxiety, and symptoms of depression, and how these interrelationships are 
associated with clinical outcomes for patients participating in a cardiac rehabilitation and 
secondary prevention program.  
Hypothesis 3a: In some individuals, anxiety sensitivity will be present, fully 
independent of symptoms of anxiety and symptoms of depression   
Hypothesis 3b: Individuals with higher levels of anxiety sensitivity will be more 
likely to report symptoms of anxiety and symptoms of depression    
Hypothesis 3c: Individuals with the concurrent presence of anxiety sensitivity, 
symptoms of anxiety, and symptoms of depression, will have the lowest levels of 
participation and completion 
Hypothesis 3d: Individuals with the concurrent presence of anxiety sensitivity, 
symptoms of anxiety, and symptoms of depression will be less likely to attain the 
expected therapeutic targets for a cardiac rehabilitation and secondary prevention 
program including increased exercise capacity, blood pressure control, and blood 
lipid control. 
Specific Aim 4: To identify key stakeholders, individuals or groups who have an interest 
in or the ability to act upon the results of the study in order to optimize the health of Cardiac 
Rehabilitation and Secondary Prevention patients.  
 92 
Specific Aim 5: To create a map of identified stakeholders that assists in visualizing the 












































SUMMARY OF QUALIFICATIONS 
 
• Trained researcher with 3 years of clinical experience 
• Exceptional written and oral communication skills applied across various styles, topics, and 
target audiences 
• Analytic and critical thinker, skilled in both abstract and detail-oriented work 
• Passionate about mentorship and leadership developmental programs  
• Exceptional organizational and management skills  





Master of Science, Pathology and Laboratory Medicine, One Health             September 2019-Present  
Western University, London, ON 
• Thesis: A One Health Approach Investigating Relationships between Anxiety Sensitivity, 
Depression, Anxiety and Clinical Outcomes in Patients Enrolled in a Cardiac Rehabilitation 
and Secondary Prevention Program 
• Demonstrating research, organization, and communication skills  
 
Bachelor of Science, Honours Life Science, Minor in Biology                                     June 2019 




AWARDS AND ACCOMPLISHMENTS 
 
• Awarded Ontario Graduate Scholarship (OGS) of $15,000 (2021) 
• Awarded Western Graduate Research Scholarship of $6,000 for high academic standing 
(2019-2021) 
• Maintained a 3.98 GPA during graduate studies (2019-2021) 
• Recognized in the Dean’s Honour List for high academic standing (2017-2019) 








MSc. Candidate September 
2019-Present 
The University of Western Ontario, London, ON 
•  Research Assistant in the Cardiac Rehabilitation and Secondary Prevention 
(CRSP) Program at St. Joseph’s Healthcare London 
•  First MSc. Cohort of One Health Program: One Health considers human health, 
animal health (translational methods), and environmental health (social 
determinants) to achieve optimal outcomes associated with non-infectious disease. 
Relevant stakeholders are identified and mapped as part of the study objectives  
•  Created 50-page study protocol comprised of background information and the 
materials and methods of my study 
•  Initiated and completed the “Research Ethics Approval” (REB) process for my 
study  
•  Experience with working with hospital approved, REDCap platform, used to set-
up survey tools and collect both clinical data and survey data 
•  Experience with performing literature searches across multiple health-related 
databases 
•  Developed the ability to critique high and low impact research papers in order to 
gain the skills and understanding to create and develop my own manuscript  
• Attended monthly seminars under the Pathology and Laboratory Medicine 
Department, tuning into guest speakers discuss clinical research relevant to the field 
of Pathology  
•  Attended weekly research meetings with the CRSP research team to discuss 
progress with my research project and other research projects being conducted in the 
program 
•  Advisory Committee meetings held every 6-months to update members of my 
research team with project milestones. 
 
Summer Research Student                                                                                                                 
May 2017-August 2017 
Microbiology Department  
Mount Sinai Health System, Toronto, ON 
• Created standard operating procedures with superiors  
• Collected data in Excel to validate the ACCELERATE PHENO System to detect 
susceptibility of hospital bacteria to various antimicrobial agents  
• Ran the BioFire FilmArray Multiplex PCR System on blood samples to detect for Candida 
species  
• Used SHIGA TOXIN QUIK CHEK to detect Shiga toxins in E. coli species via agglutination 
techniques  
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• Created Validation report for QUIK CHEK  
• Practiced technical skills such as streaking, plating, creating 0.5 McFarlan, and using 
selective agars  
• Exposed to microbiology related lab instruments such as the MALDI-TOF and VITEK 
machinery  
• Gave mini presentation to supervisors and employees of the department summarizing the 
projects and work done over the course of my employment  
 
 
VOLUNTEER EXPERIENCE  
 
Outpatient Physiotherapy Volunteer     May 2016 – August 2016 
William Osler Health System  
Etobicoke General Hospital 
 
Duties included: 
• Reviewed patient charts prior to their arrival in order to set and prep the 
following item(s): 
o Preparing patient beds  
o Prepping heat/cooling pads  
o Prepping exercise stretch bands based on incoming patient 
schedule  
• Talked to patients as they completed their designated exercise routines  
• Demonstrated leadership when new volunteers came to the clinic –
assisted them in becoming more familiar with how the clinic is run  
• Worked in collaboration with physiotherapists, physiotherapist assistance 
and other volunteers in order to deliver standard of care 
 
INTERPERSONAL AND TEACHING EXPERIENCE 
 
Graduate Teaching Assistant                                                                September 2020-Present  
Department of Pathology and Laboratory Medicine  
The University of Western Ontario, London, ON 
 
• Course: One Health 3300 – Foundations to One Health 
• Objective was to mark weekly quizzes related to conceptual frameworks, socialism, 
environmental health, animal health, human health, and their interconnectedness  
• Course: One Health 3600 – One Health in Action  
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• Objective is to continue working on the well-developed proposals from the One Health 
3300 class and assist students to work on and finalize an “action-plan” project to 
implement the One Health approach to a non-infectious or infectious disease related case. 
 
Undergraduate Teaching Assistant                                         September 2018-December 2018 
School of Interdisciplinary Science (SIS)  
McMaster University, Hamilton, ON 
• Course: Science 1A03 – Investigating Science: Opportunities & Experiences  
• Objective was to help first year university students prepare for the university career 
through different avenues  
• Lead in class sessions three times a week on applying basic research skills to analyzing 
scientific articles, working on mini-projects, and creating reflections  





Pathology and Laboratory Medicine Research Day                                                                                               
April 2021 
Department of Pathology and Laboratory Medicine 
Western University, London, ON 
• Conducted a 3-minute poster presentation of my master’s thesis followed by a 2-minute 
Q&A period  
 
Health & Rehabilitation Sciences Graduate Research Conference                                                             
February 2021 
Western Health Sciences  
Western University, London, ON 
•  Conducted a 5-minute oral presentation of my master’s thesis  
 
One Health Poster Day                                                                                                                                      
November 2020 
The Centre for Public Health and Zoonoses and the One Health Institute at the University of 
Guelph, in collaboration with the One Health Program in the Department of Pathology and 
Laboratory Medicine at the Schulich School of Medicine & Dentistry at Western University 
The University of Guelph 
•  Conducted a 2-minute live oral presentation via Microsoft Teams of my master’s 
thesis  
•  Had the opportunity to gain constructive feedback regarding my study and gain 
insight on other    research projects relevant to One Health  
 
One Health Poster Day                                                                                                                                      
November 2019 
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The Centre for Public Health and Zoonoses and the One Health Institute at the University of 
Guelph, in collaboration with the One Health Program in the Department of Pathology and 
Laboratory Medicine at the Schulich School of Medicine & Dentistry at Western University 
The University of Guelph 
•  Conducted In-Person Poster Presentation of my master’s thesis 
•  Had the opportunity to gain constructive feedback regarding my study and gain 
insight on other    research projects relevant to One Health  
 
Physician Observership                                                   September 2018-December 2018 
Oncology   
Juravinski Cancer Centre, Hamilton, Ontario 
 
• Visited patient rooms with Dr. Dhesy and observed her role as a medical oncologist  
• Observed breast exams, body CT’s, and patient history  
• Shadowed the work of the current medical residents in the department  
• Examined the roles of other practitioners that worked alongside Dr. Dhesy  
• Completed a placement project summing everything learned over the 4-month span  
 
Summer Student Research Day                                                                     August 2017 
Mount Sinai Health System, Department of Microbiology  
Toronto, Ontario 
• Conducted a 15-minute oral presentation to supervisors and employees of the department 
summarizing the projects and work done over the course of my employment at Mount 





Scoping Review – 1st Author          
Present 
Pathology and Laboratory Medicine Department  
The University of Western Ontario, London, ON 
• Manuscript (In Progress): The Relationship Between Anxiety Sensitivity and 





Mentor for Pathology and Laboratory Medicine Program                September 2020-Present 
Western University 
London, Ontario   
                
• Currently a mentor in the PaLM Program at Western University as a graduate student. I meet 
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with a 1st year MSc. student monthly to discuss any questions or advice he might need as well 
as providing social support, advocating for the importance of mental health especially during 
these uncertain times. 
 
Mentor and Alumnus of MOTION Basketball Association              
September 2014-Present  
Rexdale, Ontario  
• Attend yearly events to speak to at-risk youth about relatable experiences and how to go 
about making a change in the community 
 
Summer Science Camp Counsellor              
June 2019-August 2019 
YMCA (GTA), Mississauga, Ontario 
 
• Ran Camps for 7 weeks, running science activities for junior (ages 5-8) and senior (ages 9-
12) children. Science experiments range from making "slime" and other hands-on activities 
to performing chemical reactions for the older and more advanced groups. I was not only a 
teacher but learned to become a mentor for both kids and other staff. 
 
Member of the Black Aspiring Physicians of McMaster Association                




• Being part of the Black Aspiring Physicians of McMaster Association, I was able to both 
receive and give mentorship to fellow undergraduate students who identify as Black, hoping 
to pursue a career in healthcare. 
 
 
SKILLS & CERTIFICATIONS  
 
• Certified in Standard First Aid & CPR/AED Level C – Canadian Red Cross  
• Certified in WHMIS Training – Western University  
• Certified in Tri-Council Policy Statement (TCPS 2: Core): Ethical Conduct for Research 
Involving Humans Course on Human Ethics  
• Certified in Animal Ethics and Regulation – Western University   
• Certified in Supervisor Health and Safety Awareness – Western University  
• Certified in AODA: Accessibility and Service – Western University  
• Proficient in all Microsoft applications 
 
 
 
